William Blair Issues Pessimistic Forecast for ALLO Earnings

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Equities research analysts at William Blair reduced their Q3 2025 EPS estimates for Allogene Therapeutics in a research note issued to investors on Thursday, August 14th. William Blair analyst S. Corwin now anticipates that the company will post earnings per share of ($0.25) for the quarter, down from their previous estimate of ($0.23). The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.28) per share. William Blair also issued estimates for Allogene Therapeutics’ Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.95) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.20) EPS and FY2026 earnings at ($0.79) EPS.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.05.

A number of other research firms also recently issued reports on ALLO. Robert W. Baird cut their price target on Allogene Therapeutics from $12.00 to $9.00 and set an “outperform” rating for the company in a research note on Wednesday, May 14th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Allogene Therapeutics in a research report on Monday, August 4th. Citizens Jmp downgraded shares of Allogene Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 14th. Citigroup dropped their price target on shares of Allogene Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, May 15th. Finally, JMP Securities reaffirmed a “market perform” rating on shares of Allogene Therapeutics in a report on Monday, August 4th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, Allogene Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $8.44.

Allogene Therapeutics Stock Performance

Allogene Therapeutics stock opened at $1.10 on Monday. Allogene Therapeutics has a one year low of $0.86 and a one year high of $3.78. The stock has a fifty day moving average of $1.25 and a 200 day moving average of $1.45. The stock has a market cap of $244.07 million, a PE ratio of -0.99 and a beta of 0.35.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC bought a new position in shares of Allogene Therapeutics in the first quarter worth about $28,000. Caption Management LLC bought a new position in Allogene Therapeutics in the 4th quarter worth approximately $32,000. CANADA LIFE ASSURANCE Co grew its holdings in Allogene Therapeutics by 142.0% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 31,211 shares of the company’s stock valued at $35,000 after buying an additional 18,314 shares in the last quarter. R Squared Ltd bought a new stake in shares of Allogene Therapeutics during the second quarter valued at approximately $37,000. Finally, Engineers Gate Manager LP purchased a new position in shares of Allogene Therapeutics in the second quarter worth $37,000. Institutional investors own 83.63% of the company’s stock.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).